# Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Alexander M.M. Eggermont,Christian U. Blank,Mario Mandalà,Georgina V. Long,Victoria Atkinson,Stéphane Dalle,Andrew Haydon,Mikhail Lichinitser,Adnan Khattak,Matteo S. Carlino,Shahneen Sandhu,James Larkin,Susana Puig,Paolo A. Ascierto,Piotr Rutkowski,Dirk Schadendorf,Rutger H.T. Koornstra,Leonel F. Hernandez‐Aya,Michele Maio,Alfonsus Johannes Maria van den Eertwegh,Jean-Jacques Grob,Ralf Gutzmer,Rahima Jamal,Paul Lorigan,Nageatte Ibrahim,Sandrine Marréaud,Alexander C. J. van Akkooi,Stefan Suciu,Caroline Robert |
| Citations | 1,870 |
| DOI | 10.1056/nejmoa1802357 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://www.nejm.org/doi/pdf/10.1056/NEJMoa1802357?articleTools=true |
| OpenAlex ID | https://openalex.org/W2797309423 |
| PMID | 29658430 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Shahneen Sandhu](https://scholariq.org/researchers/shahneen-sandhu/)

## Paper journal

- [New England Journal of Medicine](https://scholariq.org/journals/new-england-journal-of-medicine/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.